drugset / Trial / NCT04724473

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

NCT04724473

Phase 0 Completed 1030 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.

Timeline

Start
2019-12-10
Primary completion
2020-11-21
Completion
2020-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tretinoin Small molecule 0.025 % Topical

Indications